A recent study indicates that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a leading health publication demonstrates that while obese people often shed about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such medications must be cognizant of the potential of rapid weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about one and a half years.
Comparing Approaches
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team point out that individuals who lose weight through diet and exercise usually have a slower weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Doctors believe the way of the drugs explains the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication results in hunger is unsuppressed, making overeating much more probable."
An Ongoing Disease?
Medical guidelines suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, given the likelihood of weight regain, the therapy might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the results "highlight the long-term character of obesity," akin to managing diseases like diabetes.
User Experiences
People who have discontinued the jabs report a sudden resurgence of appetite.
"I experienced a switch flipping and you're instantly starving," said an individual.
The struggle is worsened if individuals have not adopted lasting dietary or behavioural changes during therapy.
Significant Adoption
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is greater among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are effective agents for shedding pounds, they are not a magic fix and maintained weight loss relies on integrated behavioural changes.